166 related articles for article (PubMed ID: 37775990)
1. Population pharmacokinetic-pharmacodynamic modeling of clopidogrel for dose regimen optimization based on CYP2C19 phenotypes: A proof of concept study.
Jung YS; Jin BH; Park MS; Kim CO; Chae D
CPT Pharmacometrics Syst Pharmacol; 2024 Jan; 13(1):29-40. PubMed ID: 37775990
[TBL] [Abstract][Full Text] [Related]
2. Effect of CYP2C19 Polymorphisms on the Platelet Response to Clopidogrel and Influence on the Effect of High Versus Standard Dose Clopidogrel in Carotid Artery Stenting.
González A; Moniche F; Cayuela A; García-Lozano JR; Torrecillas F; Escudero-Martínez I; Gonzalez-Marcos JR; Mayol A; Montaner J
Eur J Vasc Endovasc Surg; 2016 Feb; 51(2):175-86. PubMed ID: 26526111
[TBL] [Abstract][Full Text] [Related]
3. Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel.
Kitazono T; Ikeda Y; Nishikawa M; Yoshiba S; Abe K; Ogawa A
J Thromb Thrombolysis; 2018 Nov; 46(4):488-495. PubMed ID: 30074128
[TBL] [Abstract][Full Text] [Related]
4. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D
Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027
[TBL] [Abstract][Full Text] [Related]
5. A Randomized Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Clopidogrel in Three Different CYP2C19 Genotype Groups of Healthy Japanese Subjects.
Kobayashi M; Kajiwara M; Hasegawa S
J Atheroscler Thromb; 2015; 22(11):1186-96. PubMed ID: 26063503
[TBL] [Abstract][Full Text] [Related]
6. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects.
Simon T; Bhatt DL; Bergougnan L; Farenc C; Pearson K; Perrin L; Vicaut E; Lacreta F; Hurbin F; Dubar M
Clin Pharmacol Ther; 2011 Aug; 90(2):287-95. PubMed ID: 21716274
[TBL] [Abstract][Full Text] [Related]
8. Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics.
Djebli N; Fabre D; Boulenc X; Fabre G; Sultan E; Hurbin F
Drug Metab Dispos; 2015 Apr; 43(4):510-22. PubMed ID: 25609219
[TBL] [Abstract][Full Text] [Related]
9. Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome.
Khalaf H; Al Meman AA; Rasool S
Drug Metab Lett; 2016; 10(1):65-70. PubMed ID: 26573281
[TBL] [Abstract][Full Text] [Related]
10. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
Braun OÖ; Angiolillo DJ; Ferreiro JL; Jakubowski JA; Winters KJ; Effron MB; Duvvuru S; Costigan TM; Sundseth S; Walker JR; Saucedo JF; Kleiman NS; Varenhorst C
Thromb Haemost; 2013 Dec; 110(6):1223-31. PubMed ID: 24009042
[TBL] [Abstract][Full Text] [Related]
11. Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects.
Song BL; Wan M; Tang D; Sun C; Zhu YB; Linda N; Fan HW; Zou JJ
Clin Ther; 2018 Jul; 40(7):1170-1178. PubMed ID: 30017169
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
Wang XQ; Shen CL; Wang BN; Huang XH; Hu ZL; Li J
Gene; 2015 Mar; 558(2):200-7. PubMed ID: 25542807
[TBL] [Abstract][Full Text] [Related]
13. Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes.
Nagashima Z; Tsukahara K; Morita S; Endo T; Sugano T; Hibi K; Himeno H; Fukui K; Umemura S; Kimura K
J Cardiol; 2013 Sep; 62(3):158-64. PubMed ID: 23886632
[TBL] [Abstract][Full Text] [Related]
14. Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity.
Barker CM; Murray SS; Teirstein PS; Kandzari DE; Topol EJ; Price MJ
JACC Cardiovasc Interv; 2010 Oct; 3(10):1001-7. PubMed ID: 20965456
[TBL] [Abstract][Full Text] [Related]
15. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 2C19 polymorphism is associated with reduced clopidogrel response in cerebrovascular disease.
Lee JB; Lee KA; Lee KY
Yonsei Med J; 2011 Sep; 52(5):734-8. PubMed ID: 21786436
[TBL] [Abstract][Full Text] [Related]
17. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100
[TBL] [Abstract][Full Text] [Related]
18. Changes in P2Y12 reaction units after switching treatments from prasugrel to clopidogrel in Japanese patients with acute coronary syndrome followed by elective coronary stenting.
Ueno T; Koiwaya H; Sasaki KI; Katsuki Y; Katsuda Y; Murasato Y; Shimamatsu J; Umeji K; Otsuka Y; Kawasaki T; Shibata Y; Fukumoto Y
Cardiovasc Interv Ther; 2017 Oct; 32(4):341-350. PubMed ID: 27488859
[TBL] [Abstract][Full Text] [Related]
19. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC
Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794
[TBL] [Abstract][Full Text] [Related]
20. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
Varenhorst C; James S; Erlinge D; Brandt JT; Braun OO; Man M; Siegbahn A; Walker J; Wallentin L; Winters KJ; Close SL
Eur Heart J; 2009 Jul; 30(14):1744-52. PubMed ID: 19429918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
